Immune Disorder HSCT Protocol
| Status: | Recruiting |
|---|---|
| Conditions: | Other Indications, Infectious Disease, HIV / AIDS, Hematology |
| Therapuetic Areas: | Hematology, Immunology / Infectious Diseases, Other |
| Healthy: | No |
| Age Range: | Any - 21 |
| Updated: | 3/28/2019 |
| Start Date: | March 2013 |
| End Date: | March 2024 |
A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Immune Function Disorders Using a Reduced Intensity Preparatory Regime
This study hypothesizes that a reduced intensity immunosuppressive preparative regimen will
establish engraftment of donor hematopoietic cells with acceptable early and delayed toxicity
in patients with immune function disorders. A regimen that maximizes host immune suppression
is expected to reduce graft rejection and optimize donor cell engraftment.
establish engraftment of donor hematopoietic cells with acceptable early and delayed toxicity
in patients with immune function disorders. A regimen that maximizes host immune suppression
is expected to reduce graft rejection and optimize donor cell engraftment.
Inclusion Criteria:
-
- Performance status >/= 40
- DLCO >/= 40%
- LVEF >/=40% or LVSF >/=26%
- Serum creatinine < 2x ULN
- Liver enzymes
- Negative pregnancy test
- Suitably matched donor (6/6 matched sib UCB, 8/8 matched sib BM or PBSC, 5-6/6 matched
unrelated UCB, 7-8/8 matched unrelated BM, double cord)
Exclusion Criteria:
- Known diagnosis of HIV I/II
- Pregnant or breastfeeding
- Uncontrolled invasive fungal or bacterial infections within 1 month prior to starting
alemtuzumab
- Uncontrolled viral infection within 1 week prior to starting alemtuzumab
We found this trial at
2
sites
Saint Louis, Missouri 63110
Principal Investigator: Jeffrey Bednarski, MD
Phone: 314-454-6018
Click here to add this to my saved trials
Click here to add this to my saved trials